Masaaki Ogasa

Title: Masaaki Ogasa: Innovator in Schizophrenia Treatment

Introduction

Masaaki Ogasa is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of schizophrenia. With a total of 2 patents, Ogasa's work focuses on innovative methods that aim to improve the quality of life for patients suffering from this complex mental health condition.

Latest Patents

Ogasa's latest patents include a novel agent for the treatment of schizophrenia. This invention provides a method that can improve a wide range of symptoms, especially positive and negative symptoms, without causing extrapyramidal symptoms. The active compound used in this treatment is (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide or its pharmaceutically acceptable salt, administered at a daily dose of 5 mg to 120 mg. Another significant patent addresses a remedy for integration dysfunction syndrome, utilizing the same active compound and method of administration.

Career Highlights

Masaaki Ogasa is currently employed at Sumitomo Dainippon Pharma Co., Ltd. His work at this esteemed company has allowed him to focus on groundbreaking research and development in the pharmaceutical industry. His dedication to improving treatment options for schizophrenia has positioned him as a key figure in this field.

Collaborations

Ogasa has collaborated with notable coworkers, including Mitsutaka Nakamura and Shunsuke Sami. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Masaaki Ogasa's innovative work in the treatment of schizophrenia showcases his commitment to enhancing patient care through scientific advancements. His contributions are vital in the ongoing quest to find effective treatments for mental health disorders.